Lung cancer ranks first in incidence and mortality among all cancers worldwide, and is a major killer of human health. More than 70% of lung cancers are locally advanced and late stage when diagnosed, losing the chance of surgical treatment, and medical treatment or combined radiotherapy is the main treatment modality. In the last decade, molecularly targeted therapy represented by epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib has become an indispensable treatment for advanced non-small cell lung cancer. Due to their high efficacy, rapid remission, low toxicity and good tolerability in sensitive populations, they have brought new hope for survival to many patients with advanced lung cancer in clinical applications. However, there are some safety-related problems in the clinical use of such drugs in recent years, mainly involving the following aspects. I. Indications: Epidermal growth factor receptor tyrosine kinase inhibitors are mainly indicated for patients with advanced non-small cell lung cancer with EGFR-sensitive mutations, and can also be used as salvage therapy (but with low efficacy) after chemotherapy for EGFR wild-type patients. There is no evidence for preoperative and postoperative treatment of patients with early-stage lung cancer. The significance of genetic testing for efficacy prediction: A large number of clinical studies have shown that the efficiency of gefitinib for EGFR mutation positive patients is 70%-90%, while the efficiency of wild-type patients is only 1-10%, so it is significant to screen the population that may benefit. C. Precautions for administration: administered orally, note that the combination with CYP3A4 inducers (such as rifampin, phenytoin, carbamazepine, barbiturates, or St. John’s wort) may reduce efficacy. Nursing mothers should be advised to discontinue breastfeeding during treatment with this product. There is no information on the safety and efficacy of this product in pediatric or adolescent patients, so its use is not recommended. IV. Common Toxicity and Related Management: EGFR tyrosine kinase inhibitors have a similar spectrum of cutaneous adverse reactions, with common manifestations including dryness (dry skin), pruritus, desquamation, nail/perineal changes (usually nail fungus), abnormal hair growth (usually manifested as alopecia, thick eyelashes, or facial hypertrichosis), and capillary dilation (usually manifested as swelling of small blood vessels and hyperpigmentation), while Papulopustular lesions (i.e., acne or acne-like rash) are the most common skin adverse reaction, with an incidence of 60%-80%. Some patients experience loss of appetite and abnormal liver function, and only 1-3% of patients develop drug-induced interstitial pneumonia, which may be life-threatening. Expert advice on dose reduction or discontinuation of EGFR-TKIs 1. Dose reduction or discontinuation of EGFR-TKIs should be used as a last resort after failure of treatment for grade III skin reactions, with erlotinib reduced to 100 mg/day and gefitinib to 250 mg every other day, and treatment interrupted only if skin reactions persist for 2-4 weeks and do not clear. 2. Treatment of rash cannot be stopped during discontinuation of EGFR-TKIs. Because the rash may last for a lot of time. 3. Some patients only need to stop the drug temporarily, and can continue the drug after the rash improves. Preventive measures 1. Patients are advised to reduce the time of sun exposure and to avoid light. The rash caused by small-molecule tyrosine kinase inhibitors is mostly photosensitive and can cause a more severe rash when exposed to sunlight. 2. Keep the body clean and dry parts of the skin moist every day. Do not touch alkaline and irritating toiletries, and apply mild moisturizer or silicone cream or vitamin E ointment after bathing to prevent dry skin. 3.It is recommended to use a broad-spectrum sunscreen with SPF>18. 4.Patients with ingrown toenails (reverse peeling) may develop nail fungus and local hyperplasia during the medication process. During the treatment of EGFR-TKIs, it is necessary to change foot stress habits and wear loose, breathable shoes; one week before EGFR-TKIs treatment, i.e. hot warm water foot soak (continue during medication) or edible salt + water + white radish slices (or pepper) (boil) and apply skin care products or silicone cream after foot soak can prevent foot occurrence of rashes. Aggressive treatment of tinea pedis. Treatment of rash, dry skin and itching 1. Mild toxicity: Patients may not need any form of intervention, but can also use topical dermaplanin, hydrocortisone (10% or 25% ointment) or clindamycin (10% gel), erythromycin ointment. For dry skin with itching, thin phenol glycerin lotion twice daily or benadryl ointment may be applied to the itchy area. The dose of EGFR-TKIs should not be changed due to mild toxicity, and the rash should be re-evaluated after 2 weeks and treated for moderate toxicity if it worsens or does not improve significantly. 2. Moderate toxicity: Topical 2.5% hydrocortisone ointment or erythromycin ointment, and oral capretin. For dry skin with itching, benadryl ointment or compound benzoic acid ointment should be applied to the itchy area 1-2 times daily. The rash should be re-evaluated after 2 weeks; if the situation worsens or does not improve significantly, proceed to the next level of treatment. 3. Severe rash: interventions are basically the same as for moderate rash, but the drug dose can be increased appropriately. If necessary, shock dose of methylprednisolone can be given, and the dose of EGFR-TKIs can be reduced; if combined with infection, choose the appropriate antimicrobial for treatment, such as cefuroxime 250mgbid, and consider suspending the drug or discontinuing the treatment if the adverse effects are not fully relieved after 2-4 weeks. V. Purchase route: It is recommended to buy from regular hospitals or pharmacies, not to buy generic products on the Internet or other channels (e.g., generic products produced in India, etc.)